title: Drug interactions with statins.
abstract: The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. Statins are substrates of multiple drug transporters (including OAT- -P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review summarizes the most important interactions of statins.
authors.forename: Anida
authors.initials: A
authors.lastname: Causevic-Ramosevac
authors.forename: Sabina
authors.initials: S
authors.lastname: Semiz
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000378:metabolism / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions / Q000502:physiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000378:metabolism*; D011480:Protease Inhibitors / Q000378:metabolism / Q000627:therapeutic use; D013379:Substrate Specificity / Q000187:drug effects
chemical_list: D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011480:Protease Inhibitors; C400322:cytochrome P-450 CYP2C subfamily; D003577:Cytochrome P-450 Enzyme System